25 XP   0   0   10

Xiangxue Pharmaceutical
Buy, Hold or Sell?

Let's analyse Xiangxue Pharmaceutical together

PenkeI guess you are interested in Xiangxue Pharmaceutical. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Xiangxue Pharmaceutical. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Xiangxue Pharmaceutical

I send you an email if I find something interesting about Xiangxue Pharmaceutical.

Quick analysis of Xiangxue Pharmaceutical (30 sec.)










What can you expect buying and holding a share of Xiangxue Pharmaceutical? (30 sec.)

How much money do you get?

How much money do you get?
¥0.03
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
¥4.06
Expected worth in 1 year
¥3.46
How sure are you?
85.0%

+ What do you gain per year?

Total Gains per Share
¥-0.35
Return On Investment
-9.5%

For what price can you sell your share?

Current Price per Share
¥3.67
Expected price per share
¥3 - ¥4.78
How sure are you?
50%

1. Valuation of Xiangxue Pharmaceutical (5 min.)




Live pricePrice per Share (EOD)

¥3.67

Intrinsic Value Per Share

¥5.44 - ¥6.54

Total Value Per Share

¥9.50 - ¥10.60

2. Growth of Xiangxue Pharmaceutical (5 min.)




Is Xiangxue Pharmaceutical growing?

Current yearPrevious yearGrowGrow %
How rich?$370.5m$490.2m-$107.6m-28.1%

How much money is Xiangxue Pharmaceutical making?

Current yearPrevious yearGrowGrow %
Making money-$13.1m-$34.6m$21.5m163.8%
Net Profit Margin-19.8%-37.0%--

How much money comes from the company's main activities?

3. Financial Health of Xiangxue Pharmaceutical (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#141 / 1007

Most Revenue
#47 / 1007

Most Profit
#938 / 1007

Most Efficient
#486 / 1007

What can you expect buying and holding a share of Xiangxue Pharmaceutical? (5 min.)

Welcome investor! Xiangxue Pharmaceutical's management wants to use your money to grow the business. In return you get a share of Xiangxue Pharmaceutical.

What can you expect buying and holding a share of Xiangxue Pharmaceutical?

First you should know what it really means to hold a share of Xiangxue Pharmaceutical. And how you can make/lose money.

Speculation

The Price per Share of Xiangxue Pharmaceutical is ¥3.67. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Xiangxue Pharmaceutical.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Xiangxue Pharmaceutical, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥4.06. Based on the TTM, the Book Value Change Per Share is ¥-0.15 per quarter. Based on the YOY, the Book Value Change Per Share is ¥-0.52 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.06 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Xiangxue Pharmaceutical.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps-0.02-0.5%-0.02-0.6%-0.05-1.4%-0.01-0.4%0.00-0.1%
Usd Book Value Change Per Share-0.02-0.4%-0.02-0.6%-0.07-2.0%-0.01-0.4%0.010.2%
Usd Dividend Per Share0.010.2%0.010.2%0.010.3%0.010.3%0.010.4%
Usd Total Gains Per Share-0.01-0.2%-0.01-0.3%-0.06-1.6%0.00-0.1%0.020.5%
Usd Price Per Share0.75-0.77-0.93-1.00-1.55-
Price to Earnings Ratio-11.15--10.18--10.24-11.49-38.86-
Price-to-Total Gains Ratio-98.83--58.34-96.33-55.03-87.71-
Price to Book Ratio1.33-1.33-1.24-1.27-2.53-
Price-to-Total Gains Ratio-98.83--58.34-96.33-55.03-87.71-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.506827
Number of shares1973
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.01
Usd Book Value Change Per Share-0.02-0.01
Usd Total Gains Per Share-0.010.00
Gains per Quarter (1973 shares)-23.70-6.70
Gains per Year (1973 shares)-94.81-26.81
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
167-162-10585-112-37
2134-324-200171-225-64
3201-485-295256-337-91
4268-647-390342-449-118
5335-809-485427-562-145
6402-971-580513-674-172
7469-1133-675598-786-199
8536-1295-770684-898-226
9603-1456-865769-1011-253
10670-1618-960855-1123-280

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%2.010.00.016.7%8.012.00.040.0%26.012.02.065.0%39.012.02.073.6%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%10.010.00.050.0%29.011.00.072.5%39.014.00.073.6%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%53.00.00.0100.0%
Total Gains per Share1.03.00.025.0%6.06.00.050.0%14.06.00.070.0%34.06.00.085.0%46.07.00.086.8%

Fundamentals of Xiangxue Pharmaceutical

About Xiangxue Pharmaceutical

Xiangxue Pharmaceutical Co., Ltd. engages in the research and development, procurement, manufacture, delivery, and distribution of pharmaceutical products in China. It offers antivirotic oral liquids under the Xiangxue brand name; and healthcare supplements, as well as health solutions, such as food and beverage. Xiangxue Pharmaceutical Co., Ltd. has strategic partnership agreement with 111, Inc. to develop the Internet + Medicine model for China's traditional Chinese medicine industry. Xiangxue Pharmaceutical Co., Ltd. was founded in 1997 and is based in Guangzhou, China.

Fundamental data was last updated by Penke on 2024-04-16 12:35:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Xiangxue Pharmaceutical.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Xiangxue Pharmaceutical earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Xiangxue Pharmaceutical to the Biotechnology industry mean.
  • A Net Profit Margin of -15.2% means that ¥-0.15 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Xiangxue Pharmaceutical:

  • The MRQ is -15.2%. The company is making a huge loss. -2
  • The TTM is -19.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-15.2%TTM-19.8%+4.6%
TTM-19.8%YOY-37.0%+17.3%
TTM-19.8%5Y-10.5%-9.3%
5Y-10.5%10Y-1.3%-9.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.2%-207.2%+192.0%
TTM-19.8%-218.5%+198.7%
YOY-37.0%-282.4%+245.4%
5Y-10.5%-432.2%+421.7%
10Y-1.3%-593.8%+592.5%
1.1.2. Return on Assets

Shows how efficient Xiangxue Pharmaceutical is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Xiangxue Pharmaceutical to the Biotechnology industry mean.
  • -0.9% Return on Assets means that Xiangxue Pharmaceutical generated ¥-0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Xiangxue Pharmaceutical:

  • The MRQ is -0.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -1.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-0.9%TTM-1.0%+0.2%
TTM-1.0%YOY-2.3%+1.3%
TTM-1.0%5Y-0.6%-0.5%
5Y-0.6%10Y0.1%-0.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.9%-13.2%+12.3%
TTM-1.0%-12.6%+11.6%
YOY-2.3%-11.5%+9.2%
5Y-0.6%-13.7%+13.1%
10Y0.1%-15.5%+15.6%
1.1.3. Return on Equity

Shows how efficient Xiangxue Pharmaceutical is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Xiangxue Pharmaceutical to the Biotechnology industry mean.
  • -3.5% Return on Equity means Xiangxue Pharmaceutical generated ¥-0.04 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Xiangxue Pharmaceutical:

  • The MRQ is -3.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -4.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.5%TTM-4.0%+0.5%
TTM-4.0%YOY-8.7%+4.7%
TTM-4.0%5Y-2.3%-1.7%
5Y-2.3%10Y-0.5%-1.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.5%-16.7%+13.2%
TTM-4.0%-15.8%+11.8%
YOY-8.7%-14.4%+5.7%
5Y-2.3%-19.0%+16.7%
10Y-0.5%-19.9%+19.4%

1.2. Operating Efficiency of Xiangxue Pharmaceutical.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Xiangxue Pharmaceutical is operating .

  • Measures how much profit Xiangxue Pharmaceutical makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Xiangxue Pharmaceutical to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Xiangxue Pharmaceutical:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM1.4%-1.4%
TTM1.4%YOY-11.8%+13.2%
TTM1.4%5Y3.5%-2.1%
5Y3.5%10Y2.2%+1.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.5%+286.5%
TTM1.4%-229.1%+230.5%
YOY-11.8%-288.4%+276.6%
5Y3.5%-480.7%+484.2%
10Y2.2%-624.7%+626.9%
1.2.2. Operating Ratio

Measures how efficient Xiangxue Pharmaceutical is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.65 means that the operating costs are ¥1.65 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Xiangxue Pharmaceutical:

  • The MRQ is 1.650. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.628. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.650TTM1.628+0.022
TTM1.628YOY1.850-0.222
TTM1.6285Y1.644-0.016
5Y1.64410Y1.173+0.471
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6503.231-1.581
TTM1.6283.307-1.679
YOY1.8503.774-1.924
5Y1.6445.667-4.023
10Y1.1737.558-6.385

1.3. Liquidity of Xiangxue Pharmaceutical.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Xiangxue Pharmaceutical is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.35 means the company has ¥0.35 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Xiangxue Pharmaceutical:

  • The MRQ is 0.348. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.309. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.348TTM0.309+0.039
TTM0.309YOY0.390-0.080
TTM0.3095Y0.695-0.386
5Y0.69510Y0.426+0.269
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3483.890-3.542
TTM0.3094.182-3.873
YOY0.3905.343-4.953
5Y0.6956.135-5.440
10Y0.4266.453-6.027
1.3.2. Quick Ratio

Measures if Xiangxue Pharmaceutical is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Xiangxue Pharmaceutical to the Biotechnology industry mean.
  • A Quick Ratio of 0.12 means the company can pay off ¥0.12 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Xiangxue Pharmaceutical:

  • The MRQ is 0.120. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.128. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.120TTM0.128-0.008
TTM0.128YOY0.192-0.064
TTM0.1285Y0.296-0.168
5Y0.29610Y0.450-0.155
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1203.528-3.408
TTM0.1284.059-3.931
YOY0.1925.390-5.198
5Y0.2966.138-5.842
10Y0.4506.488-6.038

1.4. Solvency of Xiangxue Pharmaceutical.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Xiangxue Pharmaceutical assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Xiangxue Pharmaceutical to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.71 means that Xiangxue Pharmaceutical assets are financed with 70.8% credit (debt) and the remaining percentage (100% - 70.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Xiangxue Pharmaceutical:

  • The MRQ is 0.708. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.701. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.708TTM0.701+0.007
TTM0.701YOY0.668+0.033
TTM0.7015Y0.606+0.095
5Y0.60610Y0.536+0.070
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7080.339+0.369
TTM0.7010.337+0.364
YOY0.6680.273+0.395
5Y0.6060.368+0.238
10Y0.5360.391+0.145
1.4.2. Debt to Equity Ratio

Measures if Xiangxue Pharmaceutical is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Xiangxue Pharmaceutical to the Biotechnology industry mean.
  • A Debt to Equity ratio of 288.2% means that company has ¥2.88 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Xiangxue Pharmaceutical:

  • The MRQ is 2.882. The company is unable to pay all its debts with equity. -1
  • The TTM is 2.766. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ2.882TTM2.766+0.116
TTM2.766YOY2.539+0.227
TTM2.7665Y1.954+0.811
5Y1.95410Y1.502+0.452
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8820.388+2.494
TTM2.7660.403+2.363
YOY2.5390.342+2.197
5Y1.9540.432+1.522
10Y1.5020.461+1.041

2. Market Valuation of Xiangxue Pharmaceutical

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Xiangxue Pharmaceutical generates.

  • Above 15 is considered overpriced but always compare Xiangxue Pharmaceutical to the Biotechnology industry mean.
  • A PE ratio of -11.15 means the investor is paying ¥-11.15 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Xiangxue Pharmaceutical:

  • The EOD is -7.577. Based on the earnings, the company is expensive. -2
  • The MRQ is -11.148. Based on the earnings, the company is expensive. -2
  • The TTM is -10.180. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.577MRQ-11.148+3.571
MRQ-11.148TTM-10.180-0.968
TTM-10.180YOY-10.241+0.061
TTM-10.1805Y11.491-21.671
5Y11.49110Y38.864-27.373
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.577-2.249-5.328
MRQ-11.148-2.553-8.595
TTM-10.180-2.669-7.511
YOY-10.241-4.107-6.134
5Y11.491-6.247+17.738
10Y38.864-6.499+45.363
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Xiangxue Pharmaceutical:

  • The EOD is 19.451. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 28.621. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 13.926. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD19.451MRQ28.621-9.169
MRQ28.621TTM13.926+14.695
TTM13.926YOY98.620-84.695
TTM13.9265Y17.069-3.143
5Y17.06910Y13.495+3.573
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD19.451-2.858+22.309
MRQ28.621-3.288+31.909
TTM13.926-3.552+17.478
YOY98.620-5.560+104.180
5Y17.069-8.326+25.395
10Y13.495-8.881+22.376
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Xiangxue Pharmaceutical is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.33 means the investor is paying ¥1.33 for each ¥1 in book value.

Let's take a look of the Price to Book Ratio trends of Xiangxue Pharmaceutical:

  • The EOD is 0.904. Based on the equity, the company is cheap. +2
  • The MRQ is 1.331. Based on the equity, the company is underpriced. +1
  • The TTM is 1.328. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.904MRQ1.331-0.426
MRQ1.331TTM1.328+0.003
TTM1.328YOY1.238+0.090
TTM1.3285Y1.266+0.062
5Y1.26610Y2.529-1.262
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.9041.929-1.025
MRQ1.3312.090-0.759
TTM1.3282.091-0.763
YOY1.2382.881-1.643
5Y1.2663.545-2.279
10Y2.5293.936-1.407
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Xiangxue Pharmaceutical compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.111-0.148+33%-0.523+370%-0.103-7%0.040-377%
Book Value Per Share--4.0584.189-3%5.368-24%5.737-29%5.260-23%
Current Ratio--0.3480.309+13%0.390-11%0.695-50%0.426-18%
Debt To Asset Ratio--0.7080.701+1%0.668+6%0.606+17%0.536+32%
Debt To Equity Ratio--2.8822.766+4%2.539+14%1.954+47%1.502+92%
Dividend Per Share--0.0570.061-8%0.087-35%0.078-28%0.098-42%
Eps---0.121-0.172+42%-0.380+213%-0.098-19%-0.024-80%
Free Cash Flow Per Share--0.0470.017+175%-0.011+124%-0.089+288%-0.209+544%
Free Cash Flow To Equity Per Share--0.047-0.160+439%-0.242+612%-0.181+484%-0.002+105%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.950+5%
Intrinsic Value_10Y_max--6.537--------
Intrinsic Value_10Y_min--5.443--------
Intrinsic Value_1Y_max--0.136--------
Intrinsic Value_1Y_min--0.133--------
Intrinsic Value_3Y_max--0.805--------
Intrinsic Value_3Y_min--0.760--------
Intrinsic Value_5Y_max--1.950--------
Intrinsic Value_5Y_min--1.776--------
Market Cap2426893841.920-47%3570906843.0003680017885.425-3%4430902045.150-19%4799568750.831-26%7445871985.476-52%
Net Profit Margin---0.152-0.198+30%-0.370+144%-0.105-31%-0.013-92%
Operating Margin---0.014-100%-0.1180%0.035-100%0.022-100%
Operating Ratio--1.6501.628+1%1.850-11%1.644+0%1.173+41%
Pb Ratio0.904-47%1.3311.328+0%1.238+8%1.266+5%2.529-47%
Pe Ratio-7.577+32%-11.148-10.180-9%-10.241-8%11.491-197%38.864-129%
Price Per Share3.670-47%5.4005.565-3%6.700-19%7.257-26%11.259-52%
Price To Free Cash Flow Ratio19.451-47%28.62113.926+106%98.620-71%17.069+68%13.495+112%
Price To Total Gains Ratio-67.169+32%-98.831-58.343-41%96.333-203%55.031-280%87.708-213%
Quick Ratio--0.1200.128-6%0.192-37%0.296-59%0.450-73%
Return On Assets---0.009-0.010+17%-0.023+162%-0.006-34%0.001-1365%
Return On Equity---0.035-0.040+14%-0.087+145%-0.023-35%-0.005-87%
Total Gains Per Share---0.055-0.087+59%-0.436+698%-0.025-55%0.138-139%
Usd Book Value--370594133.916382567006.269-3%490251742.716-24%524027224.197-29%480415873.758-23%
Usd Book Value Change Per Share---0.015-0.021+33%-0.072+370%-0.014-7%0.006-377%
Usd Book Value Per Share--0.5600.579-3%0.741-24%0.792-29%0.726-23%
Usd Dividend Per Share--0.0080.008-8%0.012-35%0.011-28%0.014-42%
Usd Eps---0.017-0.024+42%-0.052+213%-0.014-19%-0.003-80%
Usd Free Cash Flow--4307594.9141566130.080+175%-1021138.240+124%-8109925.198+288%-15766131.981+466%
Usd Free Cash Flow Per Share--0.0070.002+175%-0.002+124%-0.012+288%-0.029+544%
Usd Free Cash Flow To Equity Per Share--0.007-0.022+439%-0.033+612%-0.025+484%0.000+105%
Usd Market Cap335154039.569-47%493142235.018508210469.977-3%611907572.435-19%662820444.490-26%1028274921.194-52%
Usd Price Per Share0.507-47%0.7460.769-3%0.925-19%1.002-26%1.555-52%
Usd Profit---11058994.148-13139266.989+19%-34663872.213+213%-8421557.957-24%-1918076.427-83%
Usd Revenue--72755088.74774907189.422-3%85612471.252-15%92557511.935-21%78608470.734-7%
Usd Total Gains Per Share---0.008-0.012+59%-0.060+698%-0.003-55%0.019-139%
 EOD+4 -4MRQTTM+18 -17YOY+19 -155Y+7 -2810Y+9 -27

3.2. Fundamental Score

Let's check the fundamental score of Xiangxue Pharmaceutical based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-7.577
Price to Book Ratio (EOD)Between0-10.904
Net Profit Margin (MRQ)Greater than0-0.152
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.120
Current Ratio (MRQ)Greater than10.348
Debt to Asset Ratio (MRQ)Less than10.708
Debt to Equity Ratio (MRQ)Less than12.882
Return on Equity (MRQ)Greater than0.15-0.035
Return on Assets (MRQ)Greater than0.05-0.009
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of Xiangxue Pharmaceutical based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.310
Ma 20Greater thanMa 503.792
Ma 50Greater thanMa 1003.968
Ma 100Greater thanMa 2004.458
OpenGreater thanClose3.670
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in CNY. All numbers in thousands.

Summary
Total Assets9,186,899
Total Liabilities6,503,379
Total Stockholder Equity2,256,290
 As reported
Total Liabilities 6,503,379
Total Stockholder Equity+ 2,256,290
Total Assets = 9,186,899

Assets

Total Assets9,186,899
Total Current Assets1,888,651
Long-term Assets7,298,248
Total Current Assets
Cash And Cash Equivalents 130,959
Net Receivables 652,501
Inventory 504,958
Other Current Assets 78,551
Total Current Assets  (as reported)1,888,651
Total Current Assets  (calculated)1,366,969
+/- 521,683
Long-term Assets
Property Plant Equipment 5,406,063
Goodwill 199,720
Intangible Assets 1,351,860
Long-term Assets Other 34,098
Long-term Assets  (as reported)7,298,248
Long-term Assets  (calculated)6,991,742
+/- 306,506

Liabilities & Shareholders' Equity

Total Current Liabilities5,421,619
Long-term Liabilities1,081,760
Total Stockholder Equity2,256,290
Total Current Liabilities
Short Long Term Debt 1,510,373
Accounts payable 903,190
Other Current Liabilities 85,827
Total Current Liabilities  (as reported)5,421,619
Total Current Liabilities  (calculated)2,499,390
+/- 2,922,229
Long-term Liabilities
Long term Debt 815,388
Capital Lease Obligations Min Short Term Debt12,928
Long-term Liabilities Other 64,220
Long-term Liabilities  (as reported)1,081,760
Long-term Liabilities  (calculated)892,537
+/- 189,223
Total Stockholder Equity
Total Stockholder Equity (as reported)2,256,290
Total Stockholder Equity (calculated)0
+/- 2,256,290
Other
Capital Stock661,279
Common Stock Shares Outstanding 661,279
Net Debt 2,194,803
Net Invested Capital 4,582,051
Net Working Capital -3,532,968
Property Plant and Equipment Gross 5,406,063



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302009-12-312008-12-312007-12-31
> Total Assets 
553,433
551,471
698,315
735,732
754,960
1,846,628
1,709,694
1,878,290
1,920,086
1,921,138
1,963,532
2,083,616
2,258,017
2,949,032
2,967,262
2,839,352
3,419,484
3,474,708
3,556,462
3,577,232
3,469,500
3,588,283
3,541,620
5,087,490
4,587,434
4,652,002
4,693,135
5,699,354
7,573,415
7,988,727
8,830,050
8,541,767
8,626,668
9,240,687
9,254,947
9,697,766
8,836,380
8,625,609
8,773,329
8,261,818
8,561,810
8,063,293
9,556,232
9,813,566
9,938,317
9,778,169
9,878,793
11,604,762
11,636,375
11,380,592
11,170,462
10,941,414
9,334,274
9,353,001
9,320,481
9,211,381
9,186,899
9,186,8999,211,3819,320,4819,353,0019,334,27410,941,41411,170,46211,380,59211,636,37511,604,7629,878,7939,778,1699,938,3179,813,5669,556,2328,063,2938,561,8108,261,8188,773,3298,625,6098,836,3809,697,7669,254,9479,240,6878,626,6688,541,7678,830,0507,988,7277,573,4155,699,3544,693,1354,652,0024,587,4345,087,4903,541,6203,588,2833,469,5003,577,2323,556,4623,474,7083,419,4842,839,3522,967,2622,949,0322,258,0172,083,6161,963,5321,921,1381,920,0861,878,2901,709,6941,846,628754,960735,732698,315551,471553,433
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,200,097
4,267,675
3,918,586
4,014,996
3,209,350
3,280,057
2,696,900
3,963,615
3,833,234
3,819,715
3,720,721
3,736,334
2,697,484
2,668,695
3,086,002
2,899,025
2,608,051
1,529,851
1,693,187
1,700,580
1,657,478
1,888,651
1,888,6511,657,4781,700,5801,693,1871,529,8512,608,0512,899,0253,086,0022,668,6952,697,4843,736,3343,720,7213,819,7153,833,2343,963,6152,696,9003,280,0573,209,3504,014,9963,918,5864,267,6755,200,09700000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,765,544
787,556
650,107
517,020
651,186
568,752
495,694
1,229,270
1,102,239
1,057,122
605,136
475,854
214,700
164,816
196,122
356,834
215,765
166,960
166,503
142,993
127,450
130,959
130,959127,450142,993166,503166,960215,765356,834196,122164,816214,700475,854605,1361,057,1221,102,2391,229,270495,694568,752651,186517,020650,107787,5561,765,54400000000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
508,680
0
479,844
474,104
36,456
23,310
28,544
14,694
26,102
22,080
19,337
4,463
4,714
3,083
65,626
58,614
75,892
231
126
55
0
0
005512623175,89258,61465,6263,0834,7144,46319,33722,08026,10214,69428,54423,31036,456474,104479,8440508,68000000000000000000000000000000000000
       Net Receivables 
15,843
29,701
66,508
42,740
57,299
94,425
108,128
117,581
131,787
100,546
110,727
134,210
125,555
183,797
172,588
175,853
338,655
405,129
413,726
406,292
474,669
506,190
501,537
513,643
575,045
679,586
669,527
1,061,059
1,069,286
1,151,734
1,201,570
1,227,285
1,154,338
2,172,708
2,536,235
1,889,631
1,997,717
2,037,066
1,036,918
1,036,093
1,079,643
1,037,409
1,226,015
1,133,221
1,199,529
1,959,849
2,110,076
1,292,320
1,297,184
1,566,476
1,322,524
1,241,199
669,929
778,168
602,612
840,258
652,501
652,501840,258602,612778,168669,9291,241,1991,322,5241,566,4761,297,1841,292,3202,110,0761,959,8491,199,5291,133,2211,226,0151,037,4091,079,6431,036,0931,036,9182,037,0661,997,7171,889,6312,536,2352,172,7081,154,3381,227,2851,201,5701,151,7341,069,2861,061,059669,527679,586575,045513,643501,537506,190474,669406,292413,726405,129338,655175,853172,588183,797125,555134,210110,727100,546131,787117,581108,12894,42557,29942,74066,50829,70115,843
       Inventory 
19,817
23,604
30,243
52,375
46,724
54,222
66,888
93,550
90,187
89,353
99,113
110,572
120,512
128,726
139,665
142,544
210,694
224,592
250,411
241,152
251,076
284,296
287,233
309,747
328,501
341,750
335,243
464,914
520,869
503,133
491,640
503,767
532,343
504,547
0
557,702
573,986
590,062
533,569
521,608
633,905
756,406
1,021,985
1,199,969
1,150,204
839,810
888,620
850,240
861,508
761,464
709,491
674,645
427,031
467,075
507,635
490,782
504,958
504,958490,782507,635467,075427,031674,645709,491761,464861,508850,240888,620839,8101,150,2041,199,9691,021,985756,406633,905521,608533,569590,062573,986557,7020504,547532,343503,767491,640503,133520,869464,914335,243341,750328,501309,747287,233284,296251,076241,152250,411224,592210,694142,544139,665128,726120,512110,57299,11389,35390,18793,55066,88854,22246,72452,37530,24323,60419,817
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,758,333
5,052,468
5,281,753
5,363,239
5,592,617
5,980,332
6,118,602
6,057,449
6,142,459
8,907,278
8,967,680
8,294,590
8,271,438
8,333,363
7,804,422
7,659,813
7,619,900
7,553,903
7,298,248
7,298,2487,553,9037,619,9007,659,8137,804,4228,333,3638,271,4388,294,5908,967,6808,907,2786,142,4596,057,4496,118,6025,980,3325,592,6175,363,2395,281,7535,052,4684,758,33300000000000000000000000000000000000000
       Property Plant Equipment 
401,127
417,744
458,681
487,718
434,271
496,799
463,506
676,431
628,660
760,551
788,532
938,730
969,482
1,129,559
1,074,851
1,198,823
1,143,837
1,433,435
1,323,335
1,357,759
1,397,399
1,481,557
1,493,530
1,536,616
1,557,371
1,620,878
1,699,405
1,903,061
3,392,051
2,866,060
2,915,798
3,033,794
3,097,613
2,399,870
2,501,757
2,582,498
2,636,621
2,683,417
2,742,423
2,830,336
3,153,286
3,293,803
3,454,584
3,631,280
3,725,447
3,489,443
3,620,777
5,824,235
5,855,498
5,956,578
5,942,195
5,998,655
5,627,318
5,525,483
5,492,596
5,451,075
5,406,063
5,406,0635,451,0755,492,5965,525,4835,627,3185,998,6555,942,1955,956,5785,855,4985,824,2353,620,7773,489,4433,725,4473,631,2803,454,5843,293,8033,153,2862,830,3362,742,4232,683,4172,636,6212,582,4982,501,7572,399,8703,097,6133,033,7942,915,7982,866,0603,392,0511,903,0611,699,4051,620,8781,557,3711,536,6161,493,5301,481,5571,397,3991,357,7591,323,3351,433,4351,143,8371,198,8231,074,8511,129,559969,482938,730788,532760,551628,660676,431463,506496,799434,271487,718458,681417,744401,127
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
423,704
423,704
423,704
422,528
422,528
422,528
422,528
422,528
422,528
610,464
621,615
634,536
634,536
635,815
635,815
646,661
646,661
646,661
646,661
644,667
644,667
644,667
644,667
626,610
626,610
626,610
626,610
626,610
626,610
626,610
626,610
266,597
266,597
266,597
199,720
199,720
199,720
199,720
199,720
199,720199,720199,720199,720199,720266,597266,597266,597626,610626,610626,610626,610626,610626,610626,610626,610644,667644,667644,667644,667646,661646,661646,661646,661635,815635,815634,536634,536621,615610,464422,528422,528422,528422,528422,528422,528423,704423,704423,704000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
334,818
334,818
366,193
407,736
470,961
471,685
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000471,685470,961407,736366,193334,818334,81800000000000000000000000000000000000
       Intangible Assets 
48,442
13,621
0
11,376
69,452
10,485
67,893
37,340
180,485
33,713
179,226
32,487
185,220
32,411
223,670
31,258
625,562
40,492
592,936
597,590
596,908
601,585
600,785
603,282
604,132
660,944
658,405
863,302
882,214
900,445
898,539
896,710
916,549
1,027,290
1,028,050
424,252
425,230
687,218
683,362
370,960
714,326
721,627
715,259
897,140
949,160
973,961
990,893
1,475,840
1,477,534
1,429,770
1,435,131
1,423,308
1,367,177
1,367,021
1,361,257
1,356,898
1,351,860
1,351,8601,356,8981,361,2571,367,0211,367,1771,423,3081,435,1311,429,7701,477,5341,475,840990,893973,961949,160897,140715,259721,627714,326370,960683,362687,218425,230424,2521,028,0501,027,290916,549896,710898,539900,445882,214863,302658,405660,944604,132603,282600,785601,585596,908597,590592,93640,492625,56231,258223,67032,411185,22032,487179,22633,713180,48537,34067,89310,48569,45211,376013,62148,442
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
229,335
345,295
248,342
217,614
277,764
305,932
4,028,766
241,512
179,156
208,335
201,511
69,476
63,067
87,506
77,733
30,950
29,478
34,387
34,098
34,09834,38729,47830,95077,73387,50663,06769,476201,511208,335179,156241,5124,028,766305,932277,764217,614248,342345,295229,33500000000000000000000000000000000000000
> Total Liabilities 
361,983
354,936
360,690
417,813
414,084
476,010
326,391
513,630
527,109
502,160
578,646
670,251
813,274
1,412,466
1,406,591
1,304,257
1,797,096
1,764,699
1,800,649
1,820,984
1,647,112
1,717,076
1,627,018
1,629,005
1,070,819
1,106,022
1,107,714
2,014,435
3,852,707
4,304,373
5,114,801
4,786,399
4,826,893
5,356,955
5,249,296
5,671,426
4,790,081
4,613,340
4,718,086
4,157,786
4,404,763
3,943,099
5,349,605
5,571,187
5,671,700
5,525,135
5,593,530
7,157,430
7,176,205
7,622,814
7,454,739
7,291,291
6,257,993
6,534,819
6,498,400
6,454,295
6,503,379
6,503,3796,454,2956,498,4006,534,8196,257,9937,291,2917,454,7397,622,8147,176,2057,157,4305,593,5305,525,1355,671,7005,571,1875,349,6053,943,0994,404,7634,157,7864,718,0864,613,3404,790,0815,671,4265,249,2965,356,9554,826,8934,786,3995,114,8014,304,3733,852,7072,014,4351,107,7141,106,0221,070,8191,629,0051,627,0181,717,0761,647,1121,820,9841,800,6491,764,6991,797,0961,304,2571,406,5911,412,466813,274670,251578,646502,160527,109513,630326,391476,010414,084417,813360,690354,936361,983
   > Total Current Liabilities 
136,444
265,986
291,520
359,746
361,017
403,796
255,076
309,095
322,624
294,418
368,134
559,281
603,010
707,316
706,636
653,352
916,571
1,018,166
1,058,815
1,080,899
999,895
1,137,350
1,046,421
1,049,427
494,630
563,858
566,410
1,275,071
2,358,545
3,301,139
4,087,941
3,658,001
3,683,100
3,235,466
3,235,731
3,428,485
2,625,748
3,222,436
3,324,132
2,490,595
2,682,545
2,856,107
4,237,382
4,445,269
4,507,029
4,380,027
4,373,976
6,082,011
6,157,987
6,944,299
6,652,838
6,504,003
5,511,401
5,852,556
5,805,332
5,401,174
5,421,619
5,421,6195,401,1745,805,3325,852,5565,511,4016,504,0036,652,8386,944,2996,157,9876,082,0114,373,9764,380,0274,507,0294,445,2694,237,3822,856,1072,682,5452,490,5953,324,1323,222,4362,625,7483,428,4853,235,7313,235,4663,683,1003,658,0014,087,9413,301,1392,358,5451,275,071566,410563,858494,6301,049,4271,046,4211,137,350999,8951,080,8991,058,8151,018,166916,571653,352706,636707,316603,010559,281368,134294,418322,624309,095255,076403,796361,017359,746291,520265,986136,444
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,000
105,200
852,900
1,933,009
1,344,000
1,569,500
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000001,569,5001,344,0001,933,009852,900105,20030,00000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,000
105,200
852,900
1,933,009
1,344,000
1,569,500
1,410,500
2,706,250
2,834,810
2,908,040
2,881,304
2,421,007
2,413,693
2,084,798
2,466,299
2,520,712
2,479,351
1,850,287
1,926,083
1,978,191
1,506,179
1,510,373
1,510,3731,506,1791,978,1911,926,0831,850,2872,479,3512,520,7122,466,2992,084,7982,413,6932,421,0072,881,3042,908,0402,834,8102,706,2501,410,5001,569,5001,344,0001,933,009852,900105,20030,00000000000000000000000000000000000000
       Accounts payable 
39,260
118,724
76,182
63,961
60,915
79,182
71,988
91,861
89,367
79,357
60,308
89,760
108,654
110,271
104,071
118,226
177,669
221,308
205,004
205,106
190,535
250,067
223,230
204,133
225,696
238,909
216,820
436,141
446,080
517,604
463,054
497,370
415,238
461,056
422,437
463,903
397,645
451,436
454,261
455,671
631,011
707,721
682,967
777,829
799,084
801,001
911,798
900,696
1,033,024
1,122,753
1,035,261
959,013
748,713
841,313
860,803
882,112
903,190
903,190882,112860,803841,313748,713959,0131,035,2611,122,7531,033,024900,696911,798801,001799,084777,829682,967707,721631,011455,671454,261451,436397,645463,903422,437461,056415,238497,370463,054517,604446,080436,141216,820238,909225,696204,133223,230250,067190,535205,106205,004221,308177,669118,226104,071110,271108,65489,76060,30879,35789,36791,86171,98879,18260,91563,96176,182118,72439,260
       Other Current Liabilities 
46,284
53,262
74,838
54,785
40,102
64,614
48,088
62,234
68,257
62,561
125,326
89,521
64,356
83,045
88,565
106,126
184,902
382,858
359,811
318,793
232,359
252,282
181,191
218,294
216,934
282,949
287,590
320,220
308,466
439,751
390,588
340,454
361,371
376,410
343,419
293,109
447,151
400,763
482,000
372,800
406,988
361,645
473,755
442,689
472,183
501,914
882,007
2,539,303
2,800,283
2,831,923
2,726,021
2,709,296
2,637,447
2,970,907
90,024
2,716,843
85,827
85,8272,716,84390,0242,970,9072,637,4472,709,2962,726,0212,831,9232,800,2832,539,303882,007501,914472,183442,689473,755361,645406,988372,800482,000400,763447,151293,109343,419376,410361,371340,454390,588439,751308,466320,220287,590282,949216,934218,294181,191252,282232,359318,793359,811382,858184,902106,12688,56583,04564,35689,521125,32662,56168,25762,23448,08864,61440,10254,78574,83853,26246,284
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,393,955
1,667,191
1,722,218
1,076,904
1,112,224
1,125,918
1,164,670
1,145,108
1,219,555
1,075,419
1,018,218
678,516
801,901
787,288
746,592
682,263
693,068
1,053,121
1,081,760
1,081,7601,053,121693,068682,263746,592787,288801,901678,5161,018,2181,075,4191,219,5551,145,1081,164,6701,125,9181,112,2241,076,9041,722,2181,667,1911,393,95500000000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-30,000
-105,200
-852,900
-1,933,009
-1,344,000
-1,569,500
0
0
0
0
0
0
890
0
2,359
2,275
1,688
885
24,919
22,339
23,133
12,928
12,92823,13322,33924,9198851,6882,2752,3590890000000-1,569,500-1,344,000-1,933,009-852,900-105,200-30,00000000000000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,307,270
1,512,120
1,568,974
938,205
963,551
976,225
0
36,064
39,664
43,264
76,370
16,580
125,079
44,796
44,796
49,630
51,286
59,303
64,220
64,22059,30351,28649,63044,79644,796125,07916,58076,37043,26439,66436,0640976,225963,551938,2051,568,9741,512,1201,307,27000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
231,429
254,960
106,691
121,994
135,880
149,505
158,854
175,539
340,593
418,002
395,456
425,184
442,343
451,663
429,514
437,101
441,787
426,240
440,651
0
453,709
0
0453,7090440,651426,240441,787437,101429,514451,663442,343425,184395,456418,002340,593175,539158,854149,505135,880121,994106,691254,960231,42900000000000000000000000000000000000
> Total Stockholder Equity
178,937
182,096
320,545
295,360
318,020
1,347,639
1,360,536
1,341,019
1,368,637
1,394,138
1,359,803
1,387,596
1,438,856
1,483,319
1,507,671
1,481,310
1,533,400
1,605,437
1,644,296
1,638,885
1,700,948
1,743,892
1,782,780
3,325,924
3,377,980
3,407,686
3,439,193
3,382,705
3,405,869
3,396,596
3,418,700
3,443,946
3,466,199
3,461,903
3,444,185
3,453,775
3,463,239
3,430,591
3,460,975
3,486,565
3,501,602
3,496,996
3,582,204
3,611,199
3,619,320
3,616,536
3,641,159
3,676,319
3,645,832
2,945,553
2,891,018
2,775,751
2,648,593
2,405,133
2,405,287
2,336,435
2,256,290
2,256,2902,336,4352,405,2872,405,1332,648,5932,775,7512,891,0182,945,5533,645,8323,676,3193,641,1593,616,5363,619,3203,611,1993,582,2043,496,9963,501,6023,486,5653,460,9753,430,5913,463,2393,453,7753,444,1853,461,9033,466,1993,443,9463,418,7003,396,5963,405,8693,382,7053,439,1933,407,6863,377,9803,325,9241,782,7801,743,8921,700,9481,638,8851,644,2961,605,4371,533,4001,481,3101,507,6711,483,3191,438,8561,387,5961,359,8031,394,1381,368,6371,341,0191,360,5361,347,639318,020295,360320,545182,096178,937
   Common Stock
81,000
81,000
92,000
92,000
92,000
123,000
123,000
246,000
246,000
246,000
246,000
295,200
300,973
300,973
301,581
392,055
392,055
392,055
391,980
391,980
509,573
509,573
509,573
661,476
661,476
661,476
661,476
661,476
661,476
661,476
661,476
661,476
661,476
661,476
661,476
661,476
661,476
661,476
661,476
661,476
661,476
661,476
661,476
661,476
661,476
661,476
661,476
661,361
661,361
661,361
661,361
661,279
661,279
0
0
661,279
0
0661,27900661,279661,279661,361661,361661,361661,361661,476661,476661,476661,476661,476661,476661,476661,476661,476661,476661,476661,476661,476661,476661,476661,476661,476661,476661,476661,476661,476661,476661,476661,476509,573509,573509,573391,980391,980392,055392,055392,055301,581300,973300,973295,200246,000246,000246,000246,000123,000123,00092,00092,00092,00081,00081,000
   Retained Earnings 
72,757
72,715
118,609
93,522
116,179
135,230
148,176
128,651
156,272
173,693
139,357
167,133
204,511
222,571
243,835
217,490
269,580
309,965
407,345
398,628
460,692
505,729
544,388
530,007
582,025
614,234
645,756
588,065
611,640
600,881
623,407
649,463
671,747
666,820
692,840
700,785
738,868
703,419
641,352
716,323
731,331
804,612
890,505
914,410
921,160
825,734
850,358
876,042
842,629
138,416
84,036
-32,042
-160,243
-500,117
-495,580
-460,736
-646,189
-646,189-460,736-495,580-500,117-160,243-32,04284,036138,416842,629876,042850,358825,734921,160914,410890,505804,612731,331716,323641,352703,419738,868700,785692,840666,820671,747649,463623,407600,881611,640588,065645,756614,234582,025530,007544,388505,729460,692398,628407,345309,965269,580217,490243,835222,571204,511167,133139,357173,693156,272128,651148,176135,230116,17993,522118,60972,71572,757
   Capital Surplus 000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000-71,886-42,636-42,6360000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-176
455
3,256
2,709
-46,673
-46,643
-36,454
-36,112
-35,119
-37,843
4,204
4,204
3,973
4,907
2,068
1,914
2,724
3,768
-5,193
0
-7,898
0
0-7,8980-5,1933,7682,7241,9142,0684,9073,9734,2044,204-37,843-35,119-36,112-36,454-46,643-46,6732,7093,256455-17600000000000000000000000000000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue2,169,651
Cost of Revenue-1,431,880
Gross Profit737,770737,770
 
Operating Income (+$)
Gross Profit737,770
Operating Expense-2,067,675
Operating Income101,975-1,329,905
 
Operating Expense (+$)
Research Development76,083
Selling General Administrative389,048
Selling And Marketing Expenses-
Operating Expense2,067,675465,131
 
Net Interest Income (+$)
Interest Income4,136
Interest Expense-225,797
Other Finance Cost-8,951
Net Interest Income-230,612
 
Pretax Income (+$)
Operating Income101,975
Net Interest Income-230,612
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-371,441101,975
EBIT - interestExpense = -225,797
-380,573
-154,776
Interest Expense225,797
Earnings Before Interest and Taxes (EBIT)--145,645
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-371,441
Tax Provision--5,553
Net Income From Continuing Ops-365,888-365,888
Net Income-380,573
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-230,612
 

Technical Analysis of Xiangxue Pharmaceutical
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Xiangxue Pharmaceutical. The general trend of Xiangxue Pharmaceutical is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Xiangxue Pharmaceutical's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Xiangxue Pharmaceutical.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 3.7 < 4.74 < 4.78.

The bearish price targets are: 3.32 > 3 > 3.

Tweet this
Xiangxue Pharmaceutical Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Xiangxue Pharmaceutical. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Xiangxue Pharmaceutical Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Xiangxue Pharmaceutical. The current macd is -0.14603166.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Xiangxue Pharmaceutical price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Xiangxue Pharmaceutical. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Xiangxue Pharmaceutical price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Xiangxue Pharmaceutical Daily Moving Average Convergence/Divergence (MACD) ChartXiangxue Pharmaceutical Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Xiangxue Pharmaceutical. The current adx is 24.14.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Xiangxue Pharmaceutical shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Xiangxue Pharmaceutical Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Xiangxue Pharmaceutical. The current sar is 3.3288.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Xiangxue Pharmaceutical Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Xiangxue Pharmaceutical. The current rsi is 44.31. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Xiangxue Pharmaceutical Daily Relative Strength Index (RSI) ChartXiangxue Pharmaceutical Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Xiangxue Pharmaceutical. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Xiangxue Pharmaceutical price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Xiangxue Pharmaceutical Daily Stochastic Oscillator ChartXiangxue Pharmaceutical Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Xiangxue Pharmaceutical. The current cci is -29.79879122.

Xiangxue Pharmaceutical Daily Commodity Channel Index (CCI) ChartXiangxue Pharmaceutical Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Xiangxue Pharmaceutical. The current cmo is -7.72885512.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Xiangxue Pharmaceutical Daily Chande Momentum Oscillator (CMO) ChartXiangxue Pharmaceutical Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Xiangxue Pharmaceutical. The current willr is -53.94736842.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Xiangxue Pharmaceutical is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Xiangxue Pharmaceutical Daily Williams %R ChartXiangxue Pharmaceutical Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Xiangxue Pharmaceutical.

Xiangxue Pharmaceutical Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Xiangxue Pharmaceutical. The current atr is 0.18295284.

Xiangxue Pharmaceutical Daily Average True Range (ATR) ChartXiangxue Pharmaceutical Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Xiangxue Pharmaceutical. The current obv is 614,375,728.

Xiangxue Pharmaceutical Daily On-Balance Volume (OBV) ChartXiangxue Pharmaceutical Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Xiangxue Pharmaceutical. The current mfi is 40.82.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Xiangxue Pharmaceutical Daily Money Flow Index (MFI) ChartXiangxue Pharmaceutical Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Xiangxue Pharmaceutical.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-26BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-27RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-19RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-02-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-13ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Xiangxue Pharmaceutical Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Xiangxue Pharmaceutical based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.310
Ma 20Greater thanMa 503.792
Ma 50Greater thanMa 1003.968
Ma 100Greater thanMa 2004.458
OpenGreater thanClose3.670
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Xiangxue Pharmaceutical with someone you think should read this too:
  • Are you bullish or bearish on Xiangxue Pharmaceutical? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Xiangxue Pharmaceutical? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Xiangxue Pharmaceutical

I send you an email if I find something interesting about Xiangxue Pharmaceutical.


Comments

How you think about this?

Leave a comment

Stay informed about Xiangxue Pharmaceutical.

Receive notifications about Xiangxue Pharmaceutical in your mailbox!